Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Can the repeated filing of citizen petitions asking the FDA to take action on pending generic drug applications be a viable basis for an antitrust action?
A federal court in Delaware is about to consider that question. ShireViroPharma, a unit of Shire plc (ViroPharma), April 10 asked the U.S. Court for the District of Delaware to dismiss an antitrust complaint the FTC filed against it for allegedly abusing the citizen petition process ( FTC v. ShireViroPharma, Inc. , D. Del., No. 1:17-cv-131, brief filed 4/10/17 ).
How the court comes out on that legal point has the potential to open up more avenues of antitrust liability for the pharmaceutical industry.
In February, the Federal Trade Commission sued ViroPharma, alleging the company filed 46 baseless citizen petitions to delay entry of a generic version of its medication Vancocin D. The FTC claimed the company sought to protect monopoly profits by filing “serial, repetitive, and unsupported filings” with the Food and Drug Administration, costing buyers hundreds of millions of dollars.
The FTC’s suit marked the first time the FTC has sued over a citizen petition, but Shire ViroPharma said the FTC doesn’t have a case.
Because the FTC failed to show an ongoing or imminent violation of the law on ViroPharma’s part, the commission doesn’t even have the statutory authority to bring the case in federal court, ViroPharma said in its brief in support of its motion to dismiss the complaint.
Even if the FTC were authorized to bring the case, ViroPharma said its citizen petitioning activity was constitutionally protected activity that can’t be prosecuted under the antitrust laws.
The Noerr-Pennington doctrine provides antitrust immunity to petitioning activity unless the petitions are “objectively baseless.” The FTC’s suit, ViroPharma said, doesn’t allege the company’s petitions were “objectively baseless” and its allegations fall far short of what is required to establish sham petitioning to get around Noerr-Pennington.
“The FTC’s attempt to establish the application of the sham exception based on the alleged number of ViroPharma’s filings is meritless,” the company asserted. ViroPharma called the FTC’s complaint an “exaggerated counting exercise” using flawed arithmetic.
ViroPharma asked the court to dismiss the FTC’s suit with prejudice—meaning the government wouldn’t be allowed to refile the suit in the future.
The government’s response is due April 24.
The case is before Judge Richard G. Andrews.
Morgan, Lewis & Bockius LLP in Washington, Philadelphia and Wilmington, Del., filed the brief for ViroPharma.
To contact the reporter on this story: Dana A. Elfin in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Brian Broderick at email@example.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)